By Nono Hu, Director of Marketing, LSN

Last week, LSN released the first part of a two-part interview with Chuck Stetson, CEO, Stetson Family Office and Founder of the Global Family Office BioForum (GFOB). Part two interview continues the discussion of family office investment in early stage life science companies. Chuck will be representing GFOB at RESI Shanghai on Nov. 12^th and RESI Taipei on Nov. 14^th, hosting a Fireside Chat at both events to discuss the strategies GFOB employs to help promote early stage investing by partnering family offices with regional angel groups and incubator programs.

To register for RESI and check out the amazing content click here!

 

By Lucy Parkinson, VP of Investor Research, LSN

Cross-border investment is a growing theme in early stage life science, with investors forming global syndicates and moving new technologies toward market in multiple regions simultaneously to maximize their returns.  However, this creates significant complexities at the legal level, both from an investment perspective and also a regulatory one, not to mention creating concerns about IP protection.  Entrepreneurs are often in need of expert advice on these complexities that arise from acting globally.

RESI Shanghai Agenda

In conjunction with RESI Shanghai, our sponsors McDermott, Will & Emery are holding the 3rd China Life Science And Health Care Outbound Legal Symposium at the Ritz Carlton Pudong on November 12th.  This full day track of content from legal experts, focused on cross-border activities and investment topics, will be open to all RESI Shanghai attendees.  Additionally, McDermott, Will & Emery will present a half-day of expert legal content at RESI Taipei on November 14th.

Interview with Chuck Stetson, CEO of Stetson Family Office

By Dennis Ford, Founder & CEO, Life Science Nation; Creator of RESI Conference Series

Click to see part one of a two part interview with Chuck Stetson, CEO, Stetson Family Office and Founder of the Global Family Office BioForum (GFOB). Chuck, who is the third generation running the Stetson Family Office, is an entrepreneur, venture capitalist, and philanthropist. GFOB helps make more high quality investments in the life science arena by connecting regional family offices with regional angel groups, incubators and accelerators – essentially helping family offices around the globe participate in the funding of early stage technology assets located in their local healthcare tech hubs.

This interview, conducted by Dennis Ford, CEO, Life Science Nation and Creator of the Redefining Early Stage Investments (RESI) Conference Series, is a deep dive into how a family office views and participates in funding startups.  Chuck will be representing the GFOB at both RESI Asia events – Shanghai, November 12^th and Taipei, November 14^th. Click here to register for the events.

By Lucy Parkinson, VP of Investor Research, LSN

When LSN decided to bring RESI to Asia, we aimed to provide far more than a regional networking hub. Through our relationships with investors and technology hubs worldwide, we knew that many investment firms are looking to Asia as a source of new technologies – and conversely, many investors and major corporations based in Asia want to meet early stage startups from other parts of the world.

Due to the outreach LSN’s team has performed to technology hubs and early stage companies, RESI Asia is building up to a global showcase of early stage drugs, devices, diagnostics, and digital health innovations. We hope you can join us in Shanghai and Taipei to meet these entrepreneurs face to face.

RESI ASIA Therapeutics Companies

RESI ASIA Medical Device Companies

RESI ASIA Diagnostics Companies

RESI ASIA Digital Health Companies

RESI ASIA Service Providers

And More…

By Lucy Parkinson, VP of Investor Research, LSN

As we take RESI from city to city across the world, LSN’s content team has tailored RESI’s panels and workshops to current trends in each of the locales that have played host to RESI.  Both Shanghai and Taipei have regional expertise that have provided new panel topics.  At RESI Shanghai, those new topics include Next Generation China CRO Capability, Different Partnership Models with China, and the return of the AI in Healthcare panel.

At RESI Taipei, we will draw on the local expertise for our new panel on Smart Hospital & Homecare, plus the return of two sessions that tap into Taipei’s local expertise – Investing in Genomics and Investing in Cell & Gene Therapy.

Additionally, as a response to the Asia style of doing business, both RESI Shanghai and RESI Taipei will feature an all-day Entrepreneur Pitch Challenge where investors will provide feedback and advice to successful applicants from the RESI Innovation Challenge.

If you’d like to take part in RESI as an investor, please get in touch with us at research@lifesciencenation.com – we are interested in hearing from potential panel speakers and pitch judges.

By Karen Deyo, Senior Investor Research Analyst, LSN

RESI San Francisco has become the key venue to meet early stage investors and companies during the annual January healthcare conference week.  Millions upon millions of dollars have been invested in early stage companies following a connection at RESI SF.  In January of this year, RESI SF’s partnering system was booked to capacity, with early stage companies and investors – 1200 attendees in total – connecting all day both in scheduled and ad hoc meetings.

LSN will be launching the 2020 RESI calendar with RESI SF on January 14th at the Marine’s Memorial Club and Hotel.  For the last two years, RESI SF registration has closed early due to selling to capacity – we recommend registering early to reserve your spot for this event!